Shonan Beauty Clinic Named "2025 TOP Provider (Japan)" by Sofwave Medical; Dr. Ayaka Nishikawa Selected as "2025 Key Opinion Leader"

Clinical Excellence and Leadership in Ultrasound-Based Skin Tightening and Wrinkle Treatment Recognized on the International Stage

IRVINE, Calif. --SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization providing management support across a wide range of healthcare fields, today announced that Shonan Beauty Clinic, a network of aesthetic healthcare clinics under SBC Medical's management support, has been recognized as "2025 TOP Provider (Japan)" by Sofwave Medical Ltd. (The Regenerative Aesthetics Company™; headquartered in Irvine, California; CEO: Louis Scafuri), the developer and manufacturer of Sofwave™, a next-generation, non-invasive skin tightening and wrinkle treatment utilizing ultrasound technology. In addition, Dr. Ayaka Nishikawa, who oversees Shonan Beauty Clinic's dermatology division, has been selected as "2025 Key Opinion Leader" by Sofwave Medical Ltd. These recognitions reflect comprehensive achievements in clinical practice, including treatment volume, case accumulation, and a safety-conscious treatment framework, as well as innovative initiatives and leadership in advancing the adoption and development of Sofwave™.

Sofwave™ is a next-generation non-invasive skin lifting treatment that delivers ultrasound energy efficiently into the dermis through its proprietary SUPERB™ (Synchronous Ultrasound Parallel Beam) technology. By stimulating the production of collagen, elastin, and hyaluronic acid, it is expected to improve sagging and fine lines of the face, neck, and under-chin area, as well as overall skin quality. The device features real-time temperature monitoring with simultaneous surface cooling during treatment, making it compatible with a broad range of skin tones and types. Its minimal invasiveness and the ability to resume daily activities immediately following treatment have made it widely adopted by medical institutions across Europe, the United States, and Asia as a treatment well-suited to modern lifestyles.

At Shonan Beauty Clinic, Dr. Nishikawa and her team have worked to build a high-reproducibility, safety-focused treatment framework, conducting thorough individual assessments, designing treatment plans tailored to each customer's skin condition, and continuously accumulating clinical cases and conducting physician training. These international recognitions affirm that the clinic's day-to-day clinical practice and organizational commitment have been evaluated on a global scale.

SBC Medical remains committed to deepening its partnerships with innovative medical device manufacturers, including Sofwave Medical Ltd., and to contributing to the sound development of the aesthetic healthcare industry while continuing to deliver personalized, customer-centered medical care.

About Sofwave Medical Ltd.
Sofwave Medical Ltd. was founded in Israel in 2016 and currently operates across more than 40 countries from its headquarters in Irvine, California. Operating under the brand positioning "The Regenerative Aesthetics Company™," Sofwave Medical develops, manufactures, and distributes Sofwave™, a non-invasive skin lifting treatment incorporating its proprietary SUPERB™ ultrasound technology.

Official Website: https://sofwave.com

About Dr. Ayaka Nishikawa
After graduating from the School of Medicine at Yokohama City University, Dr. Ayaka Nishikawa joined Shonan Beauty Clinic in 2015 as a dermatologist specializing in aesthetic medicine. In 2018, she was appointed Chief Director of Dermatology and currently oversees a wide range of initiatives across the SBC Medical Group, including the development of new dermatological treatments, technical training for doctors and nurses, and safety management. Through the analysis of clinical cases, she is dedicated to promoting evidence-based medical practice and actively engages in academic activities such as presenting at domestic and international conferences and contributing to medical journals. In recognition of her achievements, she was appointed Visiting Professor at SBC Tokyo Medical University in 2023. For more information on Dr. Nishikawa’s professional profile, please visit [here].

About SBC Medical Group Holdings Incorporated
SBC Medical Group Holdings Incorporated is a Medical Services Organization　providing management support across a wide range of healthcare fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.

For more information, visit https://sbc-holdings.com
For more insights and updates from SBC Medical, follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company’s control. These forward-looking statements reflect the Company’s current views with respect to, among other things, the Company’s product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” “targets” or “hopes” or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which are accessible on the SEC’s website at www.sec.gov.

Contacts
Hikaru Fukui / Head of IR Department; E-mail: ir@sbc-holdings.com
Akiko Wakiyama / Chief Public Relations Officer; E-mail: pr@sbc.or.jp